Biologic drugs are well established treatments for a wide range of disorders, and many of these medicines have become blockbuster products. But currently available biologics still have limitations, ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

The Trump administration’s latest effort to lower drug costs is expanding to biosimilars, medications that are highly similar to biologic drugs made with or isolated from living organisms such as ...

Biologic drugs have improved how doctors treat serious illnesses. Instead of being made from chemicals, biologics are made from organic materials and grown in living cells. Biologic drugs are used ...

Opinions expressed by Digital Journal contributors are their own. Bringing a new biologic drug from concept to clinic is a complex journey fraught with technical and regulatory hurdles. For ...

The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of ...

Biosimilars provide cheaper alternatives to biologics, potentially reducing profitability for original drug makers. Long-lasting drug patents (up to 40.5 years) support sustained revenue for ...

Once the active ingredient is defined, an Applicant must select which patent, or patents, to put forward for extension. The statute permits only one PTE per regulatory review period, so the choice is ...

Lawmakers included a provision in the government funding bill passed by the House Dec. 17 that would expand the definition of biologic drugs and benefit drugmakers, according to STAT. The provision ...